

Specific immune responses and Oncolytic effects induced by EBV LMP2A-armed modified Ankara-vaccinia virus vectored vaccines in Nasopharyngeal Cancer

Liying Sun ¹, Chao Liu^{2,*} and Junping Peng ^{1,*}

¹ NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; pengjp@hotmail.com

² State Key Laboratory of Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University; liuchao66888@xmu.edu.cn

* Correspondence: pengjp@hotmail.com; liuchao66888@xmu.edu.

Table S1 Primers for detection of MVA-LMP2A virus vaccine

Gene name	Primers
<i>LMP2A</i>	(+)GCTGCAGGAAACAACCTCCCAATATCCA
	(-)AACTGGAGGGCAGCATCTAATGACC
<i>TK</i>	(+)CGGGACTATGGACGCATG
	(-)CGGTTTCCTCACCCAATCG
<i>GFP</i>	(+)CTCCAGCAGGACCATGTG
	(-)GGACGACGGCAACTACAAG

(+): forward primers; (-): reverse primers.